<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> gene (WT1) <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in peripheral blood cells was examined in 80 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) transformed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Serum anti-WT1 antibody titers were also determined in 45 patients </plain></SENT>
<SENT sid="2" pm="."><plain>Their long-term follow-up showed that the survival rate became worse as the WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> level increased </plain></SENT>
<SENT sid="3" pm="."><plain>In particular, a high WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> level was a strong predictor of a short time to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation even if adjusted by the International Prognostic Scoring System category </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, high values of anti-WT1 antibody were an independent predictor of longer survival </plain></SENT>
<SENT sid="5" pm="."><plain>These data may justify therapeutic strategies targeting WT1 molecules in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>